Table 5.
Selected civil society organization HCV activity examples
| Category | Activity | Organization(s) involved | Results and/or comments |
|---|---|---|---|
| Awareness raising | National campaign using mass media and celebrities in Georgia | Concerted effort by Georgian Harm Reduction Network, OSF Georgia, Georgia CAB, Medecins du Monde, Hepa+, New Vector and others | Large-scale treatment program implemented |
| “Demand treatment!” campaign in Ukraine | Concerted effort of 90 CSOs led by Alliance for Public Health | Community-level HCV screening to document prevalence; subsequent national and regionally/locally-funded HCV treatment programs | |
| Mobilization | HCV advocacy and policy brief research and dissemination in 11 countries | Eurasian Harm Reduction Network; Kyrgyz Harm Reduction Network; Andrey Rylkov Foundation (Russia; Treatment Preparedness Coalition (Russia); Alliance for Public Health | Evidence compiled for awareness-raising and advocacy activities |
| Drug registration, pricing, clinical trial and early access issue negotiation at EECA level | EECACommunity Adivsory Board meetings addressing AbbVie, BMS, Gilead, Janssen and Merck Sharp & Dohme | Inclusion of simeprevir on the Russian “List of Vital and Essential Medicines” and removal of telapravir, which was included due to industry price reduction (market segmentation) despite being obsolete | |
| Advocacy | DAA price reduction negotiation in Ukraine | Alliance for Public Health | USD 750 for a 12-week sofosbuvir course; USD 900 for a 12-week sofosbuvir/ledipasvir course |
| National treatment guideline modification and program endorsement advocacy neogtiations | Inclusion of DAAs in national treatment guidelines and establishment of a national and over 15 regional treatment programs; government procurement of sofosbuvir | ||
| Testing and treatment | HCV treatment for HIV-HCV coinfected PWID implementation in harm reduction programs in Ukraine | Alliance for Public Health | Global Fund support and DAAprice reduction (above) obtained |
| Contribution to national HCV guideline development/revision and strategic planning | Multiple CSOs inAzerbaijan, Georgia, Kazakhstan, Kyrgyzstan, Moldova and Ukraine | Supports appropriate policy and program implementation |